PP  Vol.4 No.3 A , June 2013
Development and Optimization of Venlafaxine Hydrochloride Sustained Release Triple Layer Tablets Adopting Quality by Design Approach
Abstract: Purpose:Venlafaxine hydrochloride sustained release formulation increases patient compliance by reducing frequency of administration and it also reduces side effects like nausea and vomiting. Hence the objective of present investigation was to develop triple layer sustained release tablets of venlafaxine HCl using xanthan gum or polyethylene oxide. Methods:The venlafaxine HCl 150 mg sustained release tablets were prepared by wet granulation technique where drug was incorporated in middle layer with part of polymer. The barrier layers were composed of remaining polymer and other excipients. The granules and tablets were characterised. Optimized batches were also tested for drug release at different pH and in presence of ethanol, for kinetics of drug release and for water uptake/swelling. Results: Preliminary trials of monolayer tablet showed burst release due to high dose and solubility of venlafaxine HCl and hence triple layer tablets were developed. Granules of middle layer exhibited good flow properties. The comparative drug release to Effexor? XR capsule 150 mg could be achieved by modulating the concentration of polymer and diluents in middle layer as well as in barrier layers. Higher amount of polyethylene oxide was required as compared to xanthan gum which may be due to high water uptake and poor gel strength of polyethylene oxide. The optimized formulations showed pH independent drug release as well as ethanol had no effect on drug release. Effexor? XR capsule and optimized batches followed Weibull kinetics for drug release. The radar diagrams showed the comparable drug release to innovator in both the optimized formulations but point to point correlation was observed in batch with xanthan gum. Conclusion: The layered matrix tablets formulated successfully using hydrophilic polymers, xanthan gum or polyethylene oxide, to sustain the release of highly soluble drug like venlafaxine HCl.
Cite this paper: S. Butani, "Development and Optimization of Venlafaxine Hydrochloride Sustained Release Triple Layer Tablets Adopting Quality by Design Approach," Pharmacology & Pharmacy, Vol. 4 No. 3, 2013, pp. 9-16. doi: 10.4236/pp.2013.43A002.

[1]   D. A. Alderman, “A Review of Cellulose Ethers in Hydrophilic Matrices for Oral Controlled-Release Dosage Forms,” International Journal of Pharmaceutics and Technology Production Manufacturing, Vol. 5, No. 3, 1984, pp. 1-9.

[2]   S. Anurag and P. Ramesh, “Design of Controlled Release Delivery Systems Using a Modified Pharmacokinetic Approach: A Case Study for Drugs Having a Short Elimination Half-Life and a Narrow Therapeutic Index,” International Journal of Pharmaceutics, Vol. 261, No. 1-2, 2003, pp. 27-41. doi:10.1016/S0378-5173(03)00267-9

[3]   N. Najib and M. S. Suleiman, “The Kinetics of Drug Release from Ethyl Cellulose Solid Dispersions,” Drug Development and Industrial Phar-macy, Vol. 11, No. 12, 1985, pp. 2169-2181. doi:10.3109/03639048509087779

[4]   M. R. Siahi, M. B. Jalali, F. Monajjemzadeh, F. Ghaffari and S. Azarmi, “Design and Evaluation of 1and 3-Layer Matrices of Verapamil Hydro-chloride for Sustaining Its Release,” AAPS PharmSciTech, Vol. 4, No. 4, 2005, Article No. 77.

[5]   U. Conte and L. Meggi, “Multi-Layer Tablets as Drug Delivery Devices: Geomatrix® Technology,” Pharmaceutical Technology Europe, Vol. 1, No. 2, 1998, pp. 1825.

[6]   L. Maggi, R. Bruni and U. Conte, “High Molecular Weight Polyethylene Oxides (PEOs) as an Alternative to HPMC in Controlled Release Dosage Forms,” International Journal of Pharmaceutics, Vol. 195, No. 1-2, 2000, pp. 229-238. doi:10.1016/S0378-5173(99)00402-0

[7]   S. H. Bariya and M. C. Gohel, “Formulation of TripleLayer Matrix Tablets of Ven-lafaxine HCl Using Xanthan Gum,” AAPS PharmSciTech, Vol. 10, No. 2, 2009, pp. 624-630. doi:10.1208/s12249-009-9244-z

[8]   N. Billa and K. H. Yuen, “Formulation Variables Affecting Drug Release from Xanthan Gum Matrices at Laboratory Scale and Pilot Scale,” AAPS PharmSciTech, Vol. 1, No. 4, 2000, pp. 35-42. doi:10.1208/pt010430

[9]   A. Lachke, “Xanthan—A Versatile Gum,” Resonance, Vol. 9, No. 10, 2004, pp. 25-33. doi:10.1007/BF02834866

[10]   M. F. Lu, L. Woodward and S. Borodkin, “Xanthan Gum and Alginate Based Controlled Re-lease Theophylline Formulations,” Drug Development of In-dustrial Pharmacy, Vol. 17, No. 14, 1991, pp. 1987-2004. doi:10.3109/03639049109048063

[11]   D. L. Munday and P. J. Cox, “Compressed Xanthan and Karaya Gum Matrices: Hydra-tion, Erosion and Drug Release Mechanisms,” International Journal of Pharmaceutics, Vol. 203, No. 1-2, 2000, pp.179-192. doi:10.1016/S0378-5173(00)00444-0

[12]   M. M. Talukdar, V. D. Mooter, P. Augustijns, T. T. Maga, N. Verbeke and R. Kinget, “In Vitro Evaluation of Xanthan Gum as a Potential Excipient for Oral Controlled Release Matrix Tablet Formula-tion,” International Journal of Pharmaceutics, Vol. 169, No. 1, 1998, pp. 105-113. doi:10.1016/S0378-5173(98)00112-4

[13]   K. Watanabe, S. Yakou, K. Takayama, Y. Machida, K. Isowa and T. Nagai, “Investigation on Rectal Absorption of Indomethacin from Sustained-Release Hydrogel Suppositories Prepared with Wa-ter-Soluble Dietary Fibers, Xanthan Gum and Locust Bean Gum,” Biological and Pharmaceutical Bulletin, Vol. 16, No. 4, 1993, pp. 391394. doi:10.1248/bpb.16.391

[14]   K. Watanabe, S. Yakou, K. Takayama, Y. Machida and T. Nagai, “Factors Affecting Prednisolone Release from Hydrogels Prepared with Water-Soluble Dietary Fibers, Xanthan and Locust Bean Gums,” Chemical and Pharmaceutical Bulletin, Vol. 40, No. 2, 1992, pp. 459-462. doi:10.1248/cpb.40.459

[15]   A. Korner, A. Larsson, L. Piculell and B. Wittgren, “Tunning the Polymer Release from Hydro-philic Matrix Tablets by Mixing Short and Long Matrix Poly-mers,” International Journal of Pharmaceutics, Vol. 94, No. 4, 2005, pp. 759-769.

[16]   L. Yang, G. Venkatesh and R. Fassihi, “Characterization of Compressibility and Compactibility of Poly(Ethylene Oxide) Polymers for Modified Release Applica-tion by Compaction Simulator,” International Journal of Pharmaceutics, Vol. 85, No. 5, 1996, pp. 1085-1090.

[17]   C. J. Kim, “Drug Release from Compressed Hydrophilic POLY-OX-WSR Tablets,” International Journal of Pharmaceutics, Vol. 84, No. 3, 1995, pp. 303-306.

[18]   M. Efentakis and M. Vlachou, “Evaluation of High Molecular Weight Poly(oxyethylene) (Polyox) Polymer: Studies of Flow Properties and Release Rate of Furosemide and Captopril from Controlled Release Hard Gelatin Capsules,” Pharmaceutical Development and Technology, Vol. 5, No. 3, 2005, pp. 339-348. doi:10.1081/PDT-100100549

[19]   S. J. Jin, Y. H. Yoo, M. S. Kim, J. S. Kim, J. S. Park and S. J. Hwang, “Paroxetine Hy-drochloride Controlled Release POLYOX® Matrix Tablets: Screening of Formulation Variables Using Plackett-Burman Screening Design,” Pharmaceutical Research, Vol. 31, No. 3, 2008, pp. 339405.

[20]   N. T. Weiss, L. Jones and J. C. Cham-berlain, “A Possible Case of Venlafaxine-Induced Ste-vens-Johnson Syndrome,” Journal of Clinical Psychiatry, Vol. 65, No. 10, 2004, pp. 1431-1433. doi:10.4088/JCP.v65n1020d

[21]   J. S. Olver, G. D. Burrows, T. R. Norman, “The Treatment of Depression with Different Formulations of Venlafaxine: A Comparative Analysis,” Human Psychopharmacology, Vol. 19, No. 1, 2004, pp. 9-16. doi:10.1002/hup.551

[22]   P. Costa, “An Alternative Method to the Evaluation of Similarity Factor in Dissolution Testing,” International Journal of Pharmaceutics, Vol. 220, No. 1-2, 2001, pp. 77-83. doi:10.1016/S0378-5173(01)00651-2

[23]   T. Higuchi, “Mechanisms of Sustained-Action Medication: Theo-retical Analysis of Rate of Release of Solid Drugs Dispersed in Solid Matrices,” Journal of Pharmaceutical Science, Vol. 54, No. 12, 1963, pp. 1145-1149. doi:10.1002/jps.2600521210

[24]   G. Ertan, H. Y. Karasulu, E. Karasulu, M. A. Ege, T. Kose and T. Guneri, “A New in Vitro/in Vivo Kinetic Correlation Method for Nitrofurantoin Matrix Tablet Formulations,” Drug Development of Industrial Pharmacy, Vol. 26, No. 7, 2000, pp. 737-743. doi:10.1081/DDC-100101292

[25]   M. C. Gohel and S. H. Bariya, “Advanced Formulation Design of Venlafaxine Hy-drochloride Coated and TripleLayer Tablets Containing Hypromellose,” Pharmaceutical Development and Technology, Vol. 14, No. 6, 2009, pp. 650-658. doi:10.3109/10837450902911911

[26]   M. C. Gohel, R. K. Parikh, M. N. Padshala, K. G. Sarvaiya and D. G. Jena, “For-mulation and Optimization of Directly Compressible Isoniazid Modified Release Matrix Tablet,” Indian Journal of Pharma-ceutical Science, Vol. 69, No. 5, 2007, pp. 640-645. doi:10.4103/0250-474X.38468

[27]   M. Bamba, F. Puisievx, J. P. Marty and J. T. Carstensen, “Release Mechanism in Gel Forming Sustained Release Formulations,” International Journal of Pharmaceutics, Vol. 2, No. 5-6, 1979, pp. 307-311. doi:10.1016/0378-5173(79)90037-1

[28]   D. S. Roy and B. D. Rohera, “Comparative Evaluation of Rate of Hydration and Matrix Erosion of HEC and HPC and Study of Drug Release from Their Matrices,” European Journal Pharmaceutical Sci-ence, Vol. 16, No. 3, 2002, pp. 193-199. doi:10.1016/S0928-0987(02)00103-3

[29]   V. P. Shah, Y. Tsong, P. Sathe and J. P. Liu, “In Vitro Dissolution Profile Comparison-Statistics and Analysis of the Similarity Factor f2,” Pharmaceutical Research, Vol. 15, No. 6, 1998, pp. 889-896. doi:10.1023/A:1011976615750

[30]   U. Conte, L. Meggi, P. Colombo, M. A. La, “Multilayered Hydrophilic Matrices as Constant Release Devices (GeomatrixTM Systems),” Journal of Control Release, Vol. 26, No. 1, 1993, pp. 39-47. doi:10.1016/0168-3659(93)90207-L

[31]   M. A. El-Nabarawi, “Modulation of Tenoxicam Release from Hydrophilic Matrix: Modulator Membrane versus Rate-Controlling Membrane,” Chemical and Pharmaceutical Bulletin, Vol. 53, No. 9, 2005, pp. 1083-1087. doi:10.1248/cpb.53.1083

[32]   FDA Alert for Healthcare Pro-fessionals, “Hydromorphone Hydrochloride Extended-Release Capsules (Marketed as PalladoneTM),” 2005.

[33]   M. J. Traynor, M. B. Brown, A. Pannala, P. Beck and G. P. Martin, “Influence of Alcohol on the Release of Tramadol from 24-h Controlled-Release Formulations during in Vitro Dissolution Experiments,” Drug Development and Industrial Pharmacy, Vol. 34, No. 8, 2008, pp. 885889. doi:10.1080/03639040801929240